Dizziness, drowsiness, nausea, flushing, and metallic taste may occur.
Extravasation from an intravenous site may cause phlebitis and sloughing. Do not administer subcutaneously.
Hypotension, bradycardia, and syncope have occurred after intramuscular or intravenous administration. Keep the patient in a recumbent position for 10–15 minutes after injection.
Urticaria and anaphylactic reactions have been reported.
Use in pregnancy. There is no reported experience, and no FDA category has been assigned.